Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

Metastatic cancers harbor complex genomic alterations. Thus, monotherapies are often suboptimal. Individualized combinations are needed in order to attenuate resistance. To help inform selection of safe starting doses for novel, two-agent, targeted drug combinations, we identified clinical trials in...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Sariah, Nikanjam, Mina, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905475/
https://www.ncbi.nlm.nih.gov/pubmed/26824502
http://dx.doi.org/10.18632/oncotarget.7023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905475/
https://www.ncbi.nlm.nih.gov/pubmed/26824502
http://dx.doi.org/10.18632/oncotarget.7023

Ejemplares similares